CeriBell (NASDAQ:CBLL – Free Report) – Research analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of CeriBell in a research report issued on Wednesday, November 13th. William Blair analyst M. Andrew expects that the company will earn ($0.28) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for CeriBell’s current full-year earnings is ($1.55) per share. William Blair also issued estimates for CeriBell’s Q2 2026 earnings at ($0.25) EPS and Q3 2026 earnings at ($0.24) EPS.
Other equities analysts have also issued reports about the company. Bank of America assumed coverage on CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $32.00 target price for the company. JPMorgan Chase & Co. initiated coverage on shares of CeriBell in a report on Tuesday, November 5th. They set an “overweight” rating and a $32.00 price objective for the company. Canaccord Genuity Group assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $30.00 target price on the stock. Canaccord Genuity Group boosted their price target on shares of CeriBell from $30.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday. Finally, TD Cowen initiated coverage on CeriBell in a research note on Tuesday, November 5th. They set a “buy” rating and a $31.00 price objective on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $31.20.
CeriBell Stock Performance
Shares of CeriBell stock opened at $26.53 on Friday. CeriBell has a 52 week low of $23.00 and a 52 week high of $29.53.
CeriBell (NASDAQ:CBLL – Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The company had revenue of $17.20 million during the quarter, compared to analyst estimates of $17.06 million.
CeriBell Company Profile
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Articles
- Five stocks we like better than CeriBell
- How to Most Effectively Use the MarketBeat Earnings Screener
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- EV Stocks and How to Profit from Them
- Top-Performing Non-Leveraged ETFs This Year
- How Can Investors Benefit From After-Hours Trading
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
